

AMENDMENTS TO THE CLAIMS

Claim 1 (Currently amended): An isolated human antibody that specifically binds to an epitope specifically bound by an antibody expressed by ~~a clone selected from the group consisting of clone S25, clone C25, clone C39, clone 1C6, clone 3D12, clone B4, clone 1F3, clone huC25, clone Ar1, clone Ar2, clone WR1(V), clone WR1(T), clone 3-1, clone 3-8, clone 3-10, and clone ING1~~, wherein said antibody binds to and neutralizes botulinum neurotoxin type A (BoNT/A).

Claims 2-4 (Canceled).

Claim 8 (Original): The antibody of claim 1, wherein said clone is huC25.

Claims 9-16 (Canceled).

Claim 17 (Currently amended): The antibody of claim 1, wherein said antibody comprises at least two variable heavy (V_H) complementarity determining regions (CDRs) of huC25~~listed in Table 4, Table 9, or Table 11~~.

Claim 18 (Currently amended): The antibody of claim 17, wherein said antibody comprises at three variable heavy (V_H) complementarity determining regions (CDRs) of HuC25~~listed in Table 4, Table 9, or Table 11~~.

Claim 19 (Currently amended): The antibody of claim 1, wherein said antibody ~~further~~ comprises a variable light (V_L) complementarity determining region (CDR) of huC25~~listed in Table 4, Table 9, or Table 11~~.

Claim 20 (Currently amended): The antibody of claim 19, wherein said antibody comprises at least two variable light (V_L) complementarity determining regions (CDRs) of huC25~~listed in Table 4, Table 9, or Table 11~~.

Claim 21 (Currently amended): The antibody of claim 20, wherein said antibody comprises three variable light (V_L) complementarity determining regions (CDRs) of huC25~~listed in Table 4, Table 9, or Table 11~~.

Claim 22 (Currently amended): The antibody of claim 1, wherein said antibody is an antibody expressed by a clone huC25~~selected from the group consisting of a clone listed in Table 4, Table 9, or Table 11.~~

Claim 23 (Original): The antibody of claim 1, wherein said antibody is a single chain Fv (scFv).

Claim 24 (Original): The antibody of claim 1, wherein said antibody is an IgG.

Claim 25 (Original): The antibody of claim 1, wherein said antibody is a Fab.

Claim 26 (Original): The antibody of claim 1, wherein said antibody is a (Fab')₂.

Claim 27 (Original): The antibody of claim 1, wherein said antibody is a (scFv')₂.

Claim 28 (Original): The antibody of claim 27, wherein said antibody is a fusion protein of two scFv fragments.

Claim 29 (Currently amended): The antibody of claim 1, wherein said antibody comprises a framework region of huC25~~listed in Table 4, Table 9, or Table 11.~~

Claim 30 (Currently amended): The antibody of claim 29, wherein said framework is a variable heavy (V_H) framework of huC25~~framework region listed in Table 4, Table 9, or Table 11.~~

Claim 31 (Currently amended): The antibody of claim 29, wherein said framework is a variable light (V_L) framework of huC25~~framework region listed in Table 4, Table 9, or Table 11.~~

Claim 32 (Currently amended): The antibody of claim 30, wherein said antibody comprises at least two variable heavy (V_H) framework regions of huC25~~listed in Table 4, Table 9, or Table 11.~~

Claim 33 (Currently amended): The antibody of claim 31, wherein said antibody comprises at least two variable light (V_L) framework regions of huC25~~listed in Table 4, Table 9, or Table 11.~~

Claim 34 (Currently amended): The antibody of claim 30, wherein said antibody comprises a variable heavy (V_H) region of huC25~~listed in Table 4, Table 9, or Table 11.~~

Claim 35 (Currently amended): The antibody of claim 31, wherein said antibody comprises a variable light (V_L) region of huC25 listed in Table 4, Table 9, or Table 11.

Claim 36 (Currently amended): An isolated anti-botulinum neurotoxin type A (anti-BoNT/A) antibody, said antibody comprising a variable heavy (V_H) complementarity determining region (CDR) listed in Table 4, Table 9, or Table 11, and wherein said antibody specifically binds to and neutralizes a botulinum neurotoxin type A, wherein said antibody binds both an A1 and an A2 toxin.

Claim 37 (Canceled).

Claim 38 (Original): The antibody of claim 36, wherein said antibody comprises at least two variable heavy (V_H) complementarity determining regions (CDRs) listed in Table 4, Table 9, or Table 11.

Claim 39 (Original): The antibody of claim 38, wherein said antibody comprises at three variable heavy (V_H) complementarity determining regions (CDRs) listed in Table 4, Table 9, or Table 11.

Claim 40 (Original): The antibody of claim 36, wherein said antibody further comprises a variable light (V_L) complementarity determining region (CDR) listed in Table 4, Table 9, or Table 11.

Claim 41 (Original): The antibody of claim 40, wherein said antibody comprises at least two variable light (V_L) complementarity determining regions (CDRs) listed in Table 4, Table 9, or Table 11.

Claim 42 (Original): The antibody of claim 41, wherein said antibody comprises three variable light (V_L) complementarity determining regions (CDRs) listed in Table 4, Table 9, or Table 11.

Claim 43 (Original): The antibody of claim 36, wherein said antibody is an antibody expressed by a clone selected from the group consisting of a clone listed in Table 4, Table 9, or Table 11.

Claim 44 (Original): The antibody of claim 36, wherein said antibody is an IgG.

Claim 45 (Original): The antibody of claim 36, wherein said antibody is a single chain Fv (scFv).

Claim 46 (Original): The antibody of claim 36, wherein said antibody is a Fab.

Claim 47 (Original): The antibody of claim 36, wherein said antibody is a (Fab')₂.

Claim 48 (Original): The antibody of claim 36, wherein said antibody is a (scFv')₂.

Claim 49 (Original): The antibody of claim 48, wherein said antibody is a fusion protein of two scFv fragments.

Claim 50 (Original): The antibody of claim 36, wherein said antibody comprises a framework region listed in Table 4, Table 9, or Table 11.

Claim 51 (Original): The antibody of claim 50, wherein said framework is a variable heavy (V_H) frame work region listed in Table 4, Table 9, or Table 11.

Claim 52 (Original): The antibody of claim 50, wherein said framework is a variable light (V_L) frame work region listed in Table 4, Table 9, or Table 11.

Claim 53 (Original): The antibody of claim 51, wherein said antibody comprises at least two variable heavy (V_H) framework regions listed in Table 4, Table 9, or Table 11.

Claim 54 (Original): The antibody of claim 52, wherein said antibody comprises at least two variable light (V_L) framework regions listed in Table 4, Table 9, or Table 11.

Claim 55 (Original): The antibody of claim 51, wherein said antibody comprises a variable heavy (V_H) region listed in Table 4, Table 9, or Table 11.

Claim 56 (Original): The antibody of claim 52, wherein said antibody comprises a variable light (V_L) region listed in Table 4, Table 9, or Table 11.

Claim 57 (Original): The antibody of claim 36, wherein antibody specifically binds to an epitope specifically bound by an antibody expressed by a clone selected from the group consisting of clone S25, clone C25, clone C39, clone 1C6, clone 3D12, clone B4, clone 1F3, clone huC25, clone Ar1, clone Ar2, clone WR1(V), clone WR1(T), clone 3-1, clone 3-8, clone 3-10, and clone ING1.

Claims 58-96 (Canceled).

Claim 97 (Currently amended): A method of making a botulinum neurotoxin type A antibody (anti-BoNT/A) that neutralizes BoNT/A, said method comprising:

contacting a plurality of antibodies with a an epitope specifically bound by an antibody expressed by a ~~clone selected from the group consisting of clone S25, clone C25, clone C39, clone 1C6, clone 3D12, clone B4, clone 1F3, clone huC25, clone Ar1, clone Ar2, clone WR1(V), clone WR1(T), clone 3-1, clone 3-8, clone 3-10, and clone ING1;~~ and

isolating an antibody that specifically binds to said epitope, wherein said antibody is a botulinum neurotoxin type A antibody that neutralizes BoNT/A.

Claims 98-103 (Canceled).

Claim 104 (Original): The antibody of claim 97, wherein said clone is huC25.

Claims 105-112 (Canceled).

Claim 113 (Original): The method of claim 97, wherein said plurality of antibodies are antibodies displayed on a surface protein of a phage.

Claim 114 (Original): The method of claim 97, wherein said plurality of antibodies are antibodies in serum from a mammal.

Claim 115 (Original): The method of claim 97, wherein said plurality of antibodies are antibodies expressed by hybridomas.

Claim 116 (Original): A composition comprising a plurality of anti-botulinum neurotoxin antibodies, wherein each antibody is specific for a different epitope of a botulinum neurotoxin, and wherein said combination of antibodies shows greater toxin neutralization than the single antibodies comprising said plurality.

Claim 117 (Original): The composition of claim 116, wherein said composition comprises a first antibody that binds and neutralizes an A1 toxin and a second antibody that binds and neutralizes an A2 toxin.

10/632,706

Page 7

Claim 118 (Canceled).